Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAttaya SuvannasankhaBKBenga KazeemPMPaul MacLeod

Discussion

Loading...

Member takes

Overview

Analysis demonstrates improved progression-free survival in relapsed/refractory multiple myeloma with belantamab mafodotin, indicating potential for better clinical practices.

Key Points

  • Belantamab mafodotin resulted in improved progression-free survival compared to alternative therapies.
  • Patients treated with belantamab mafodotin had significant clinical efficacy, achieving better overall survival.
  • Survival model developed to evaluate long-term outcomes, demonstrating its effectiveness in clinical practice.
  • Findings highlight the necessity for informed health policy decisions regarding treatment options for multiple myeloma.

Cite This Study

Suvannasankha et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da8fhttps://doi.org/10.1182/blood-2025-4041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change2025
  2. 2Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial2025 · 1 citations
  3. 3Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis2025
  4. 4Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study2025 · 4 citations
  5. 5Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis2025